Jenburkt Pharmaceuticals (524731) Q4 25/26 earnings summary

Executive summary

• Standalone audited financial statements for the quarter and year ended 31st March 2026 were approved, with the auditor issuing an unmodified opinion on the results.

• A final dividend of ₹20.70 per equity share (207% of face value) was recommended for FY 2025-26.

• The 41st Annual General Meeting is scheduled for 4th September 2026 via video conferencing.

• Appointment and re-appointment of Shri Dilip H. Bhuta as Director and Whole Time Director & CFO for a five-year term from April 2027 were approved.

Financial highlights

• Revenue from operations for FY 2025-26 was ₹17,904.00 lakhs, up from ₹15,841.25 lakhs year-over-year.

• Net profit after tax for FY 2025-26 was ₹3,473.60 lakhs, compared to ₹3,206.06 lakhs in the previous year.

• Earnings per share (EPS) for FY 2025-26 stood at ₹78.71, up from ₹72.65 year-over-year.

• Total comprehensive income for FY 2025-26 was ₹3,320.70 lakhs.

• Cash and cash equivalents at year-end were ₹557.71 lakhs, down from ₹736.48 lakhs at the previous year-end.

Outlook and guidance

• The auditor’s report notes no material uncertainty regarding the company’s ability to meet its liabilities as they fall due within one year from the balance sheet date.